Ann Arbor, MI's RetroSense Therapeutics announced a $6 million Series B funding round to fund a Phase I/II study of its gene therapy candidate for vision restoration, as well as a "a second promising gene therapy candidate." The financing brings its total haul to $13 million, including a $7 million Series A round completed earlier this year.
Doug Williams is now happy to reveal just why he stepped aside four months ago as R&D chief of Biogen. Last July, Williams signed on as "employee number one" of Codiak BioSciences, which now has an $80 million-plus commitment from some prominent early-stage investors to launch a quest into the role exosomes can play in treating cancer and a wide variety of other diseases.
Merck, angling to compete with dominant hepatitis C treatments from Gilead Sciences and AbbVie, posted positive results for its in-development combos as it works to demonstrate their ability to cure more patients faster.
France's Genfit says it is preparing to launch its Phase III study of the NASH drug elafibranor. The biotech plans to recruit 1,800 patients for the study at 200 centers worldwide.
Back in April, Nexvet Biopharma disappointed investors with the news that its lead compound, NV-01 to treat pain from osteoarthritis in dogs, was not performing well in a pivotal clinical trial and that it would be reassessing the study plan for the drug. On Monday, the company announced that it had completed that trial and, in fact, it met its primary endpoint.
Omada Health has revealed promising results from a study that looked at how well its digital health tools could help spur weight loss among Medicare members, a milestone for the company a couple of months after it roped in new funding to develop its health management program.
Quintiles has made changes to Apple's open-source ResearchKit framework. The CRO made the enhancements--the code for which it released on the GitHub repository--to make Apple's platform more suitable for the trials it oversees.
The FDA has started testing the precisionFDA platform it developed with DNAnexus. The closed beta test phase is the precursor to a more widespread rollout of the system, which the CEO of DNAnexus has described as being "the most advanced bioinformatics platform in the world."
Regeneron Pharmaceuticals, riding high with a top-selling eye drug and some promising pipeline assets, is planning to invest $150 million in its native New York, supporting 300 new jobs at its fast-growing R&D campus.
The U.S. military has awarded a $14.3 million contract to Pryor Medical Devices to conduct a clinical trial to support an FDA clearance of its balloon catheter to temporarily occlude large vessels and monitor blood pressure in a trauma emergency without the use of fluoroscopy. That would enable its use on the battlefield to more effectively treat noncompressible torso hemorrhages, which are the top cause of potentially survivable death in combat.